Article Details
Retrieved on: 2025-03-05 12:45:38
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses the FDA's approval of two denosumab biosimilars, enhancing accessibility to treatments for osteoporosis and bone metastases, primarily targeting skeletal disorders like age-related osteoporosis and bone metastasis. This approval marks significant progress in biopharma, particularly in biopharmaceuticals for bone-related ailments linked to aging and steroid-induced osteoporosis, relevant to Amgen's RANKL-targeting medications.
Article found on: www.geneonline.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here